











24. T. van den Wyngaert, M. T. Huizing, and J. B. Vermorcken. "Bisphosphonates and osteonecrosis of the jaw: cause and effect or a post hoc fallacy?" *Annals of Oncology*. 2006;17(8):1197-1204.
25. J. B. Nase and J. B. Suzuki. "Osteonecrosis of the jaw and oral bisphosphonate treatment," *Journal of the American Dental Association*. 2006 ;137(8): 1169-70.
26. C. A. Migliorati, M. M. Schubert, D. E. Peterson, and L. M. Seneda, "Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy," *Cancer* 2005;104(1):83-93.
27. Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. *Clin Ther* 2007; 29(8):1548-58.
28. Aragon-Ching JB, Ning YM, Chen CC, Latham L, Guadagnini JP, Gulley JL et al. Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents. *Cancer Invest* 2009;27(2):221-6.
29. Woo SB, Hande K, Richardson PG. Osteonecrosis of the jaw and bisphosphonates. *N Engl J Med* 2005;353(1):99-102.
30. Bamias A, Kastritis E, Bamia C. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. *J Clin Oncol* 2005; 23:8580-7.
31. Woo SB, Hellstein JW, Kalmr JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. *Ann Intern Med*. 2006; 144: 753-61.
32. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. *J Oral Maxillofacial Surg*. 2005; 63: 1567-75.
33. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws 2009 update. *J Oral Maxillofac Surg* 2009;67(5 Suppl):2-12.
34. Abu-Id MH, Warnke PH, Gottschalk J, Springer I, Wiltfang J, Acil Y et al. "Bis-phossy jaws" - high and low risk factors for bisphosphonate-induced osteonecrosis of the jaw. *J Craniomaxillofac Surg* 2008;36(2):95-103.
35. Reid IR, Bolland MJ, Grey AB. Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity? *Bone* 2007;41(3):318-20.
36. Krueger CD, West PM, Sargent M, Lodolce AE, Pickard AS. Bisphosphonate induced osteonecrosis of the jaw. *Ann Pharmacother*. 2007; 41: 276-84.
37. Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. *N Engl J Med*. 2005; 353: 99-102.
38. Rosen HN, Moses AC, Garber J. Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy. *Calcif Tissue Int* 2000;66:100-3.
39. Harper RP, Fung E. Resolution of bisphosphonate-associated osteonecrosis of the mandible: possible application for intermittent low-dose parathyroid hormone [rhPTH(1-34)]. *J Oral Maxillofac Surg* 2007;65(3):573-80.